We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

NovImmune Enters Exclusive Antibody Licensing Agreement with Genentech


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NovImmune Enters Exclusive Antibody Licensing Agreement with Genentech"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 
NovImmune, an antibody-focused research and development biotech company, has announced that it successfully entered into an exclusive licensing agreement with Genentech Inc. a member of the Roche Group for a proprietary anti-IL-17 fully human monoclonal antibody, and access to back-up antibodies.

Recently, the IL-17 signaling pathway has received significant academic and corporate interest as its manipulation may potentially provide new treatment opportunities for major medical conditions.

The anti-IL-17 antibody was generated by NovImmune’s research team and is currently in late preclinical development. Under the terms of the agreement NovImmune will receive an upfront payment and is eligible to receive clinical milestones and royalties on sales. Full financial terms have not been disclosed.

Jack Barbut, CEO, commented “We believe Genentech is the right partner for NovImmune for this program. Genentech brings an in-depth understanding of IL-17 biology and extensive experience in its ability to potentially identify patient populations that may benefit from such a compound thus maximizing chances of successful development.”

James Sabry, Vice President of Genentech Partnering, said “Genentech is very pleased to have the opportunity to work with NovImmune on the development and potential commercialization of this anti-IL-17 antibody. We are hopeful that it has the potential to benefit patients across a range of autoimmune diseases.”
Advertisement